Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
36.3M
-
Shares change
-
-954K
-
Total reported value, excl. options
-
$1.58B
-
Value change
-
-$55.2M
-
Number of buys
-
49
-
Number of sells
-
-48
-
Price
-
$43.39
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q1 2021
116 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q1 2021.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.3M shares
of 72.2M outstanding shares and own 50.3% of the company stock.
Largest 10 shareholders include FMR LLC (6.16M shares), Matrix Capital Management Company, LP (3.82M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.66M shares), VANGUARD GROUP INC (2.42M shares), VIKING GLOBAL INVESTORS LP (2.4M shares), BlackRock Inc. (2.28M shares), Redmile Group, LLC (2.22M shares), STATE STREET CORP (1.47M shares), FEDERATED HERMES, INC. (1.4M shares), and PRIMECAP MANAGEMENT CO/CA/ (1.34M shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.